CERE Overview

Appointment of Dr. Raymond Sanchez: Alto Neuroscience has appointed Dr. Raymond Sanchez to its Board of Directors, effective August 12, 2025. Dr. Sanchez brings over 20 years of experience in the life sciences and will support the company's clinical-stage precision psychiatry programs.

Alto's Mission and Pipeline: Alto Neuroscience aims to redefine psychiatry through personalized treatment options by leveraging neurobiology. The company is developing novel drug candidates for various mental health conditions, including bipolar depression and schizophrenia, utilizing their Precision Psychiatry Platform™.

Class Action Lawsuit Filed: A class action lawsuit has been initiated against Cerevel Therapeutics, Bain Capital, and Pfizer for alleged violations of federal securities laws, impacting investors who sold or held shares during specific periods related to a merger with AbbVie.

Allegations of Misleading Information: The complaint claims that Cerevel's offering documents omitted crucial information about AbbVie's acquisition interest, leading to an artificially low stock price before the merger announcement, which benefitted Bain significantly.

Class Action Filed: A class action lawsuit has been initiated against Cerevel Therapeutics, Bain Capital, and Pfizer for alleged violations of federal securities laws related to misleading statements and insider trading during a secondary stock offering and subsequent merger discussions.

Investor Support Encouraged: Faruqi & Faruqi, LLP is urging investors who suffered losses from Cerevel's stock to contact them for legal options, with a deadline approaching for those wishing to become lead plaintiffs in the case.

Class Action Lawsuit Notification: Rosen Law Firm is reminding individuals or entities who sold or disposed of Cerevel Therapeutics Holdings, Inc. shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, about their potential rights to compensation through a class action lawsuit related to the company's merger with AbbVie Inc.

Details on Legal Representation: Investors are encouraged to join the class action by contacting Rosen Law Firm for free consultations, highlighting the firm's successful track record in securities class actions and emphasizing the importance of choosing experienced legal representation.

Class Action Lawsuit Announcement: Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics between October 11, 2023, and August 1, 2024, that they may be eligible for compensation through a class action lawsuit due to alleged misleading statements related to a secondary stock offering.

Details on Participation: Interested parties can join the class action by visiting the provided link or contacting the firm directly; however, no class has been certified yet, meaning individuals are not represented unless they choose counsel.

Class Action Filed: A class action lawsuit has been initiated against Cerevel Therapeutics, Bain Capital, and Pfizer for alleged violations of federal securities laws, affecting investors who sold or held shares during specified periods related to a merger with AbbVie.

Investor Outreach: Faruqi & Faruqi, LLP is encouraging affected investors to contact them directly to discuss their legal options and the upcoming deadline to seek lead plaintiff status in the case.